罗格列酮与 2 型糖尿病患者前列腺癌风险之间无关联。

Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.

机构信息

Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.

Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

出版信息

Front Endocrinol (Lausanne). 2023 Jul 25;14:1185053. doi: 10.3389/fendo.2023.1185053. eCollection 2023.

DOI:10.3389/fendo.2023.1185053

PMID:37560306

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10407244/

Abstract

BACKGROUND

This study investigated the risk of prostate cancer in ever users and never users of rosiglitazone in diabetes patients in Taiwan.

METHODS

The nationwide database of the National Health Insurance was used to enroll male patients who had a new diagnosis of type 2 diabetes mellitus at an age ≥ 25 years from 1999 to 2005. A total of 11,495 ever users and 11,495 never users of rosiglitazone matched on propensity score were selected and they were followed up for the incidence of prostate cancer from January 1, 2006 until December 31, 2011. Cox proportional hazard model incorporated with the inverse probability of treatment weighting using the propensity score was used to estimate hazard ratios.

RESULTS

At the end of follow-up, incident cases of prostate cancer were found in 84 never users and 90 ever users of rosiglitazone. The calculated incidence was 173.20 per 100,000 person-years in never users and was 187.59 per 100,000 person-years in ever users. The overall hazard ratio (95% confidence intervals) for ever versus never users was 1.089 (0.808-1.466). The hazard ratios were 0.999 (0.643-1.552) for the first tertile (< 672 mg), 1.147 (0.770-1.709) for the second tertile (672-3584 mg) and 1.116 (0.735-1.695) for the third tertile (> 3584 mg) of cumulative dose. Sensitivity analyses consistently showed a null association between rosiglitazone and prostate cancer risk.

CONCLUSION

Rosiglitazone has a null effect on the risk of prostate cancer.

摘要

背景

本研究旨在探讨台湾地区糖尿病患者中罗格列酮的既往使用者和未使用者罹患前列腺癌的风险。

方法

本研究使用全民健康保险数据库，纳入了 1999 年至 2005 年年龄≥25 岁新诊断为 2 型糖尿病的男性患者。共纳入 11495 例罗格列酮既往使用者和 11495 例罗格列酮未使用者，通过倾向评分匹配，随访时间从 2006 年 1 月 1 日至 2011 年 12 月 31 日，以观察前列腺癌的发病情况。采用 Cox 比例风险模型结合倾向评分的逆概率治疗加权法估计风险比。

结果

随访结束时，在 84 例罗格列酮未使用者和 90 例罗格列酮曾使用者中发现了前列腺癌新发病例。未使用者的发病率为 173.20/100000 人年，曾使用者的发病率为 187.59/100000 人年。曾使用者与未使用者的总体风险比（95%置信区间）为 1.089（0.808-1.466）。累积剂量处于第一三分位数（<672mg）时，风险比为 0.999（0.643-1.552）；处于第二三分位数（672-3584mg）时，风险比为 1.147（0.770-1.709）；处于第三三分位数（>3584mg）时，风险比为 1.116（0.735-1.695）。敏感性分析结果始终显示罗格列酮与前列腺癌风险之间无关联。